How well do targeted drugs work for EGFR lung cancer?
Part of Cancer clinical trials.
This trial studies whether changes in tiny particles in your blood (called exosomes) can show how well targeted therapy is working for lung cancer with an EGFR mutation. You may be eligible if you have this type of lung cancer and are starting your first treatment with a targeted drug.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with a type of lung cancer called lung adenocarcinoma.
- Your cancer has a common EGFR mutation (like Ex19Del or L858R) but no other EGFR changes.
- You are about to start your first treatment with a targeted therapy drug, with or without chemotherapy.
- You are between 18 and 80 years old.
- You do not have any other type of cancer now or in the past.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses artificial intelligence to predict how well EGFR-targeted therapy will work for people with certain lung cancers. It looks at your imaging and genetic information to help guide treatment.
This trial tests combining two types of cancer drugs—a targeted pill that attacks a specific mutation in your lung cancer cells, followed by an immunotherapy injection when your tumor stops shrinking. The goal is to see if this combination works better than standard treatment alone.
This trial tests whether taking an EGFR-targeted pill after lung cancer surgery can lower the chance of the cancer coming back. It is for people with early-stage non-small cell lung cancer that has a specific EGFR mutation.
This study looks at why certain EGFR-positive advanced lung cancers resist third-generation EGFR tablet treatment given as the first treatment. Your body samples and scan results help researchers understand the resistance, which may guide better future care.
This study uses leftover tissue or fluid from your lung cancer to test how it responds to different drugs in the lab. The goal is to understand which treatments might work best for tumors with EGFR mutations, which could help guide future treatment decisions.
This study tests a new targeted pill (YK-029A) versus standard chemotherapy as the first treatment for advanced lung cancer with a specific EGFR mutation. It aims to see if the targeted pill works better and has fewer side effects.
Hear when a new EGFR Activating Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.